Almirall reports flat 1st-qtr 2015 sales but profits leap
Almirall (ALM: MC), Spain’s largest drugmaker, today reported first-quarter 2015 financials, posting flat revenues of 217.2 million euros ($243.7 million), though up 8% on a like (ex-Eklira) basis.
Net product sales were 180.0 million euros, down 10.7%, with other income of 37.2 million euros, up 132.5%. Earnings before interest, taxes, depreciation and amortization (EBITDA) rose 129.2% to 73.1 million euros. Normalized net income of 42.9 million euros rose 304.7%.
Last year, Almirall transferred the rights to its respiratory franchise to Anglo-Swedish drug major AstraZeneca (LSE: AZN), which included Eklira (aclidinium), and Duaklir Genuair (aclidinium/formoterol), in a deal worth a potential $1.22 billion to the Spanish firm. Almirall has now received $150.0 million from the first milestone payment from the AstraZeneca transaction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze